Elsevier

Journal of Hepatology

Volume 28, Issue 6, June 1998, Pages 1058-1063
Journal of Hepatology

Case report
Sarcoidosis associated with interferon-α therapy for chronic hepatitis C

https://doi.org/10.1016/S0168-8278(98)80357-7Get rights and content

Abstract

Background/Aims: Pulmonary side effects of interferon-α therapy of chronic hepatitis C seem to be rare. So far, only two cases of sarcoidosis in association with interferon-α treatment of chronic hepatitis C have been described.

Methods/Cases: We report on three patients who were treated with recombinant interferon-α2a for chronic hepatitis C, two of them in combination with ribavirin. These patients developed pulmonary sarcoidosis 12, 20 and 21 weeks, respectively, after beginning interferon therapy, one patient with Löfgren's syndrome. In one patient sarcoidosis emerged only afte discontinuation of interferon therapy because of treatment failure. Clinical symptoms of sarcoidosis in the three patients were suggestive of side effects of interferon-α. Interferon therapy was discontinued and spontaneous remission was observed in all three cases 5, 6 and 8 months, respectively, after the onset of symptoms.

Conclusion: The occurrence of sarcoidosis in association with interferon-α therapy for chronic hepatitis C may have been underestimated so far. This could be due to the fact that symptoms of sarcoidosis and common side effects of interferon are similar, and sarcoidosis may occur after the end of interferon therapy. We hypothesize that interferon-α as a potent stimulator for T-helper 1 (Th1) immune responses may trigger the compartmentalized Th1 reaction that has been shown to take place in sarcoidosis.

References (29)

  • K Chin et al.

    Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C

    Chest

    (1994)
  • G Dusheiko

    Side effects of alpha interferon in chronic hepatitis C

    Hepatology

    (1997)
  • Y Yufu et al.

    Interstitial pneumonia caused by interferon-alpha in chronic myelogenous leukemia [letter]

    Am J Hematol

    (1994)
  • H Teragawa et al.

    Sarcoidosis after interferon therapy for chronic active hepatitis C

    Intern Med

    (1996)
  • E Abdi et al.

    Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma

    Cancer

    (1987)
  • M Nakajima et al.

    Recurrence of sarcoidosis following interferon alpha therapy for chronic hepatitis C

    Intern Med

    (1996)
  • E Bobbio Pallavicini et al.

    Sarcoidosis following beta-interferon therapy for multiple myeloma

    Sarcoidosis

    (1995)
  • I Ohata et al.

    A case of subcutaneous sarcoid nodules induced by interferon-alpha

    Nippon Kyobu Shikkan Gakkai Zasshi

    (1994)
  • DN Mitchell et al.

    Sarcoidosis

    Am Rev Respir Dis

    (1994)
  • GW Hunninghake et al.

    Pulmonary sarcoidosis. A disorder mediated by excess helper T-lymphocyte activity at sites of disease activity

    N Engl J Med

    (981)
  • K Konishi et al.

    Spontaneous expression of the interleukin 2 receptor gene and presence of functional interleukin 2 receptors on T-lymphocytes in the blood of individuals with active pulmonary sarcoidosis

    J Clin Invest

    (1988)
  • RM Du Bois et al.

    T-lymphocytes that accumulate in the lung in sarcoidosis have evidence of recent stimulation of the T-cell antigen receptor

    Am Rev Respir Dis

    (1992)
  • RF Silver et al.

    Limited heterogeneity of biased T-cell receptor Vβ gene usage in lung but not blood T cells in active pulmonary sarcoidosis

    Immunology

    (1996)
  • J Grunewald et al.

    T-cell receptor variable gene usage by CD4+- and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients

    PNAS

    (1994)
  • Cited by (128)

    • Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins

      2023, MacSween's Pathology of the Liver, Eighth Edition
    • Drugs and Toxins

      2018, MacSween's Pathology of the Liver
    • Drug-induced Liver Injury: The Hepatic Pathologist's Approach

      2017, Gastroenterology Clinics of North America
      Citation Excerpt :

      The differential diagnosis includes infection (including unusual bacterial and rickettsial infections as well and those from fungi and mycobacteria), sarcoidosis, and primary biliary cholangitis. Although drug-induced granulomatous injury can mimic the discrete, round, well-formed granulomas of sarcoidosis (eg, with interferon alfa28), they are usually less well-defined, irregular aggregates of epithelioid histiocytes admixed with lymphocytes and eosinophils. Confluent necrosis centered on the central vein (zone 3) that mimics hypoxic-ischemic liver injury is the characteristic injury pattern of acetaminophen.

    View all citing articles on Scopus
    View full text